ArticleIndian journal of dermatology
Post Kala-Azar Dermal Leishmaniasis: Clinical Features and Differential Diagnosis.
Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage.The Journal of antimicrobial chemotherapy · 2026Review
- Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post-Kala-Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing.Clinical pharmacology and therapeutics · 2026Article
- Nondestructive lingual variant of isolated mucosal leishmaniasis in an endemic zone: A case report from Nepal.JAAD case reports · 2026Article
- A Forgotten Foe Returns: The Diagnostic Odyssey of Kala-Azar Masquerading as Myelodysplastic Syndrome in a Post-Elimination Era.Clinical case reports · 2025Article
- Article
- Visceral Leishmaniasis in Pediatrics: A Case Series and a Narrative Review with Global Insights.Tropical medicine and infectious disease · 2025Review
- An Update on Clinical and Pathogenic Spectra of Leishmaniasis.Expert reviews in molecular medicine · 2025Review
- Article
- Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India.PLoS neglected tropical diseases · 2025Article
- Vaccines in Dermatology-Present and Future: A Review.Vaccines · 2025Review
- The Impact of Anthropic and Natural Events on Leishmaniasis Burden, Control Measures, and Public Health Importance.Transboundary and emerging diseases · 2025Review
- Visceral Leishmaniasis Service Delivery in Somalia: A Comprehensive Literature Review.Research and reports in tropical medicine · 2025Review
- Cutaneous leishmaniasis: epidemiology, treatment access and translational challenges of topical therapies.Frontiers in microbiology · 2025Review
- Article
- Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.PLoS neglected tropical diseases · 2024Article
- The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.Pharmaceutics · 2024Review
- Anti-leishmanial effects of Eryngium planum and Ecbilliun elaterum methanolic extract against Leishmania major.AMB Express · 2024Article
- Case Report: An Atypical Case of Post-Kala-Azar Dermal Leishmaniasis with Ulcers and Verrucous Lesions: Clinical and Therapeutic Implications.The American journal of tropical medicine and hygiene · 2024Article
- Evaluation of Recombinase Polymerase Amplification assay for monitoring parasite load in patients with kala-azar and post kala-azar dermal leishmaniasis.PLoS neglected tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post kala-azar dermal leishmaniasis (PKDL) is a mucocutaneous disease usually seen in apparently cured, inadequately treated or untreated cases of visceral leishmaniasis and is endemic to many parts of India, Nepal, Bangladesh, and eastern Africa (Sudan, Ethiopia, Kenya). The disease usually manifests as a variable combination of hypopigmented patches, erythematous succulent papulo-plaques, and nodular lesions on the face and upper body and sometimes extending on the extremities, genitalia, and tongue. Atypical morphology and presentations are not uncommon, especially in endemic areas, which include photosensitivity, verrucous, hypertrophic, xanthomatous, and ulcerative lesions. Recognition of spectrum of mucocutaneous changes helps physicians in early initiation of treatment and in reducing disease transmission in the community. The differential diagnosis depends on the pattern of manifestations, but lepromatous leprosy is the closest mimicker. Since PKDL does not cause significant morbidity, at least initially, but the affected patients continue to act as a reservoir of the disease, active case detection is required to identify cases early to control the disease transmission in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.